⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL151485 | 1.00 | — | — | |
| SCHEMBL309609 | 1.00 | — | — | |
| SCHEMBL20403353 | 0.96 | — | — | |
| SCHEMBL11215861 | 0.78 | CHRM2 (0.32) | — | |
| SCHEMBL6239745 | 0.72 | — | — | |
| SCHEMBL6382829 | 0.72 | — | — | |
| SCHEMBL6385694 | 0.72 | — | — | |
| SCHEMBL8927903 | 0.72 | — | — | |
| SCHEMBL11387395 | 0.72 | — | — | |
| SCHEMBL12497230 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 320 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116885-A1 | ION CHANNEL MODULATORS | PRAXIS PREC MEDICINES INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260078094-A1 | ANTI-VIRAL COMPOUNDS | INFEX THERAPEUTICS LTD (GB) | 2026-03-19 | — | — | US | disclosed |
| EP-4688792-A1 | KRAS INHIBITORS | Eli Lilly and Company (US) | 2026-02-11 | — | — | EP | disclosed |
| US-12540157-B2 | Oxysterols and methods of use thereof | Sage Therapeutics, LLC (US) | 2026-02-03 | — | — | US | disclosed |
| US-20250376475-A1 | ION CHANNEL MODULATORS | PRAXIS PREC MEDICINES INC (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250333413-A1 | SUBSTITUTED PYRIDO[2,1-a]ISOQUINOLINES AS VMAT2 INHIBITORS | NEUROCRINE BIOSCIENCES INC (US) | 2025-10-30 | — | — | US | disclosed |
| EP-4606429-A2 | VMAT2 INHIBITORS AND METHODS OF USE | Neurocrine Biosciences, Inc. (US) | 2025-08-27 | — | — | EP | disclosed |
| EP-4587425-A1 | ANTI-VIRAL COMPOUNDS | Infex Therapeutics Limited (GB) | 2025-07-23 | — | — | EP | disclosed |
| US-12344615-B2 | Substituted pyridines as ion channel modulators | PRAXIS PRECISION MEDICINES, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| EP-4168409-B1 | VMAT2 INHIBITORS AND METHODS OF USE | NEUROCRINE BIOSCIENCES INC (US) | 2025-05-07 | — | — | EP | disclosed |
| EP-1891067-A2 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS, INC. (US) | 2008-02-27 | — | — | EP | disclosed |
| US-20070265304-A1 | 1,2,3,4-TETRAHYDRO-QUINOLINE DERIVATIVES AS CETP INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-15 | — | — | US | disclosed |
| US-20070265304-A1 | 1,2,3,4-TETRAHYDRO-QUINOLINE DERIVATIVES AS CETP INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-15 | — | — | US | disclosed |
| US-20070265304-A1 | 1,2,3,4-TETRAHYDRO-QUINOLINE DERIVATIVES AS CETP INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-15 | — | — | US | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| WO-2007062314-A2 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007062314-A2 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2006138347-A2 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2006-12-28 | — | — | WO | disclosed |